Daewoong Pharma's Nabota (US brand name: Jeuveau) Daewoong Pharmaceutical said on Friday that a high-dose administration of botulinum toxin Nabota (US brand name: Jeuveau) to patients with frown wrinkles showed a six-month long-lasting effect as a result of an interim analysis of a phase 2 clinical trial.
Evolus, Daewoong Pharma's US partner, conducted the latest clinical trial on 150 patients under the age of 65 with moderate to severe frown lines.
A Daewoong Pharma official explained that long-lasting effects and safety were confirmed as a result of administering high-dose Jeuveau, which is about twice the usual dose of Jeuveau, and observing the effect of improving wrinkles between the eyebrows for six months.
"We plan to undertake marketing in large-scale botulinum toxin markets such as the US, Europe, and Canada. We will prove the effectiveness and safety of Nabota and expand our global market share through consistent clinical studies," said Park Seong-soo, vice president of Daewoong Pharmaceutical.
The results of this study were recently announced at the 2023 International Master Course on Aging Science (IMCAS) held in Paris, France.